secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2022-02-14T23:59:59+00:00
Accession:  0000950170-22-001157
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix reports preliminary Q4 2021 revenue of $7.2M; core lung testing grows 49% YoY
--------------------------------------------------------------------------------

- Preliminary full-year 2021 total revenue of $54.5M, up from $45.6M in 2020.
- Core lung diagnostic testing revenue grew 49% for full-year 2021.
- Quarterly revenue excluding COVID-19 testing was $6.8M, up 22% YoY and 13% QoQ.
- Annual revenue excluding COVID-19 testing was $24.3M, up 41% YoY.
- Cash and cash equivalents as of Dec 31, 2021: $32.7M; exploring raising capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022001157/0000950170-22-001157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022001157/bdsx-20220214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-001157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer